Insmed Stock (NASDAQ:INSM), Trade Ideas

Insmed

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ABNB

ADTX

ADXN

ALBT

AMTI

ARAV

AWIN

AXLA

BCDA

BTTR

CABA

CBIO

CBUS

CLRB

CRKN

CRMT

CXAI

EDBL

EEIQ

EFSH

EGHT

ENTA

FUBO

GETY

HRYU

HSDT

INSM

MANU

NTGR

NVOS

NXGN

OLMA

QURE

RMAX

SNDL

TCOM

UPTD

VERB

WORX

ZLAB

Gainers


	Verb Technology Company, Inc.  (NASDAQ: VERB) shares jumped 164% to $1.89 after the completed and launched a technology integration and strategic relationship with global social media platform TikTok.


Why America&#39;s Car-Mart Are Trading Lower By 12%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Biotech

Health Care

General

Insmed Incorporated (NASDAQ: INSM) shares are trading higher after the company released topline results from its Phase 3 ARISE study of ARIKAYCE in patients with newly diagnosed or recurrent nontuberculous mycobacterial (NTM) lung infection caused by Mycobacterium avium complex (MAC)

Why Lung Disease Focused Stock Insmed Is Trading Higher Today?

DWAC

Hannon Armstrong Sustainable Infrastructure Capital

HASI

TLRY

TROO

VTNR

U.S. stocks traded lower, with the Dow Jones falling around 100 points on Tuesday. Here are some big stocks recording gains in today’s session.

Brady, Airbnb, Insmed And Other Big Stocks Moving Higher On Tuesday

Insmed Inc

Truist Securities analyst Nicole Germino initiates coverage on Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy rating and announces Price Target of $48.

Price Target

Initiation

Analyst Ratings

Truist Securities Initiates Coverage On Insmed with Buy Rating, Announces Price Target of $48

Barclays analyst Leon Wang maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Overweight and raises the price target from $37 to $40.

Barclays Maintains Overweight on Insmed, Raises Price Target to $40

Insmed shares are trading higher after Wells Fargo maintained an Overweight rating on the stock and maintained its price target of $55.

Wells Fargo analyst Tiago Fauth maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Overweight and maintains $55 price target.

Wells Fargo Maintains Overweight on Insmed, Maintains $55 Price Target

Insmed Incorporated To Present Nine Abstracts From Across Its Respiratory Portfolio At American Thoracic Society 2024 International Conference

- SEC Filing
On March 8, 2024, Insmed Incorporated (the &quot;Company&quot;) received notice of the exercise by AstraZeneca AB (&quot;AstraZeneca&quot;) of its second and final option under the License Agreement, dated October 4, 2016, by and between the Company and AstraZeneca (the &quot;License Agreement&quot;), to further develop and, if approved, commercialize brensocatib in the indications of chronic obstructive pulmonary disease (&quot;COPD&quot;) or asthma. The exercise of this second option will permit AstraZeneca to develop brensocatib beyond Phase 2b clinical trials and, if approved, commercialize brensocatib in the indications of COPD or asthma, upon reaching agreement after good faith negotiations resulting in terms, including financial terms, satisfactory to both the Company and AstraZeneca for such further development and commercialization. The Company and AstraZeneca each retain all discretion to determine, among other things, whether any proposed terms are acceptable to such party. The Company retains full development and commercialization rights for brensocatib in all other indications.

Contracts

On March 8, Insmed Received Notice Of Exercise By Astrazeneca AB Of Its Second And Final Option Under License Agreement, Dated Oct 4, 2016

Guggenheim analyst Vamil Divan maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $52 to $54.

Guggenheim Maintains Buy on Insmed, Raises Price Target to $54

UBS analyst Trung Huynh initiates coverage on Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy rating and announces Price Target of $46.

UBS Initiates Coverage On Insmed with Buy Rating, Announces Price Target of $46

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) reported quarterly losses of $(1.28) per share which missed the analyst consensus estimate of $(1.15) by 11.3 percent. The company reported quarterly sales of $83.70 million which beat the analyst consensus estimate of $82.76 million by 1.14 percent. This is a 41.15 percent increase over sales of $59.30 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Insmed Q4 2023 Adj EPS $(1.28) Misses $(1.15) Estimate, Sales $83.70M Beat $82.76M Estimate

Wolfe Research analyst Andy Chen initiates coverage on Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Outperform rating and announces Price Target of $42.

Wolfe Research Initiates Coverage On Insmed with Outperform Rating, Announces Price Target of $42

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BSX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/12/24</td>
<td>$59.00</td>
<td>$40.0K</td>
<td>4.0K</td>
<td>4.0K</td>
</tr>
<tr>
<td>TLRY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$3.00</td>
<td>$52.5K</td>
<td>2.5K</td>
<td>1.6K</td>
</tr>
<tr>
<td>ELAN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/19/24</td>
<td>$17.00</td>
<td>$40.3K</td>
<td>7.8K</td>
<td>824</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/26/24</td>
<td>$79.00</td>
<td>$43.8K</td>
<td>124</td>
<td>591</td>
</tr>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$35.00</td>
<td>$53.0K</td>
<td>1</td>
<td>562</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/19/24</td>
<td>$84.00</td>
<td>$39.5K</td>
<td>551</td>
<td>512</td>
</tr>
<tr>
<td>TGTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/19/24</td>
<td>$8.00</td>
<td>$507.7K</td>
<td>1.4K</td>
<td>443</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/16/24</td>
<td>$310.00</td>
<td>$153.4K</td>
<td>353</td>
<td>265</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$155.00</td>
<td>$45.7K</td>
<td>2.6K</td>
<td>214</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/15/24</td>
<td>$540.00</td>
<td>$45.4K</td>
<td>1.0K</td>
<td>201</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding BSX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), we observe a call option sweep with bearish sentiment. It expires in 4 day(s) on January 12, 2024. Parties traded 1991 contract(s) at a $59.00 strike. This particular call needed to be split into 25 different trades to become filled. The total cost received by the writing party (or parties) was $40.0K, with a price of $20.0 per contract. There were 4063 open contracts at this strike prior to today, and today 4018 contract(s) were bought and sold. 
• For TLRY (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>), we notice a call option trade that happens to be bullish, expiring in 739 day(s) on January 16, 2026. This event was a transfer of 500 contract(s) at a $3.00 strike. The total cost received by the writing party (or parties) was $52.5K, with a price of $105.0 per contract. There were 2550 open contracts at this strike prior to today, and today 1619 contract(s) were bought and sold. 
• For ELAN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>), we notice a call option sweep that happens to be bearish, expiring in 102 day(s) on April 19, 2024. This event was a transfer of 350 contract(s) at a $17.00 strike. This particular call needed to be split into 10 different trades to become filled. The total cost received by the writing party (or parties) was $40.3K, with a price of $115.0 per contract. There were 7891 open contracts at this strike prior to today, and today 824 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a call option trade that happens to be bullish, expiring in 18 day(s) on January 26, 2024. This event was a transfer of 200 contract(s) at a $79.00 strike. The total cost received by the writing party (or parties) was $43.8K, with a price of $219.0 per contract. There were 124 open contracts at this strike prior to today, and today 591 contract(s) were bought and sold. 
• Regarding INSM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), we observe a call option trade with bearish sentiment. It expires in 347 day(s) on December 20, 2024. Parties traded 68 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $53.0K, with a price of $780.0 per contract. There were 1 open contracts at this strike prior to today, and today 562 contract(s) were bought and sold. 
• For GILD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), we notice a call option sweep that happens to be bullish, expiring in 11 day(s) on January 19, 2024. This event was a transfer of 500 contract(s) at a $84.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $39.5K, with a price of $79.0 per contract. There were 551 open contracts at this strike prior to today, and today 512 contract(s) were bought and sold. 
• Regarding TGTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>), we observe a call option trade with bearish sentiment. It expires in 11 day(s) on January 19, 2024. Parties traded 403 contract(s) at a $8.00 strike. The total cost received by the writing party (or parties) was $507.7K, with a price of $1260.0 per contract. There were 1448 open contracts at this strike prior to today, and today 443 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a call option sweep with bullish sentiment. It expires in 39 day(s) on February 16, 2024. Parties traded 198 contract(s) at a $310.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $153.4K, with a price of $775.0 per contract. There were 353 open contracts at this strike prior to today, and today 265 contract(s) were bought and sold. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a put option sweep with bullish sentiment. It expires in 165 day(s) on June 21, 2024. Parties traded 102 contract(s) at a $155.00 strike. This particular put needed to be split into 17 different trades to become filled. The total cost received by the writing party (or parties) was $45.7K, with a price of $448.0 per contract. There were 2633 open contracts at this strike prior to today, and today 214 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option trade with neutral sentiment. It expires in 67 day(s) on March 15, 2024. Parties traded 23 contract(s) at a $540.00 strike. The total cost received by the writing party (or parties) was $45.4K, with a price of $1978.0 per contract. There were 1042 open contracts at this strike prior to today, and today 201 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AMGN

ELAN

GILD

TGTX

10 Health Care Stocks With Whale Alerts In Today's Session

—ARIKAYCE&#xAE; (amikacin liposome inhalation suspension) Delivers Full-Year 2023 Revenues Exceeding the Upper End of Guidance Range with Unaudited Global Net Product Sales of Approximately $305.2 Million—
—2024 Global ARIKAYCE Revenues Expected to be Between $340 Million and $360 Million, Reflecting Double-Digit Growth Compared to 2023—
—Topline Data from the Phase 3 ASPEN Study of Brensocatib in Adult Patients with Bronchiectasis Remains on Track to Read Out in the Latter Part of Second-Quarter 2024—
—Enrollment in the Phase 2 Study of TPIP in Patients with PH-ILD Completed in November 2023; Topline Data Expected in Second-Quarter 2024—
BRIDGEWATER, N.J., Jan. 5, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today provided an update on the Company's four pillars and outlook for 2024. These updates will be discussed as part of the Company's presentation at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 8, 2024, at 3:00 p.m. PT (6:00 p.m. ET).
"The year ahead will mark the most transformational period in Insmed's history as we strive to become the&nbsp;next great biotechnology company," said Will Lewis, Chair and Chief Executive Officer of Insmed. "From the readout of our highly anticipated Phase 3 ASPEN study, to our first Phase 2 topline TPIP data, to the advancement of our ARIKAYCE label expansion program, 2024 is the moment we have been waiting for. Each of these three programs, if successful, has the potential to achieve peak sales of more than $1 billion. Over the next 12 months, we have the opportunity to truly break out from the pack, delivering tangible results for our shareholders, while, more importantly, making a meaningful impact in the lives of patients with serious and rare diseases."
Preliminary Full Year 2023 Global Net Product Sales (Unaudited)
Based on preliminary unaudited financial information, the Company expects total global net product sales of ARIKAYCE to be approximately $305.2 million for the full year 2023, with net sales across the United States, Japan, and Europe as follows. This represents 24% year-over-year growth from the full year 2022, including growth in the U.S. of 21% and in Japan of 16%.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2" rowspan="1">Preliminary Unaudited Full Year 2023 Global Net Product Sales by Region</td>
</tr>
<tr>
<td colspan="1" rowspan="1">United States</td>
<td colspan="1" rowspan="1">$224.2 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Japan</td>
<td colspan="1" rowspan="1">$65.7 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Europe</td>
<td colspan="1" rowspan="1">$15.3 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total</td>
<td colspan="1" rowspan="1">$305.2 million</td>
</tr>
</tbody>
</table>
</figure>
These preliminary unaudited results are subject to adjustment.&nbsp;Insmed will report its final and complete fourth-quarter and full-year 2022 financial results in late February 2024, and the actual results could be materially different from these preliminary unaudited financial results.
Progress and Anticipated Milestones by Pillar:
Pillar 1: ARIKAYCE
<ul>
<li>Insmed anticipates 2024 global ARIKAYCE revenues to be between $340 million and $360 million, representing 15% year-over-year growth at the midpoint compared to 2023.</li>
<li>The Company has completed its original target enrollment of 250 patients in the ENCORE trial in patients with newly diagnosed or recurrent nontuberculous mycobacterial lung infection caused by Mycobacterium avium complex (MAC) who had not started antibiotics. Enrollment in the study remains ongoing.</li>
<li>Insmed received encouraging written feedback from the U.S. Food and Drug Administration (FDA) on the patient-reported outcome data produced in the Phase 3 ARISE study in December 2023. As expected, the Company will seek a meeting with the Agency in the coming months to gain additional insights and guidance, from which it will finalize its statistical plans for the Phase 3 ENCORE study, including an updated enrollment target for the study.</li>
<li>The Company continues to anticipate a topline readout for ENCORE in 2025.</li>
</ul>
Pillar 2: Brensocatib
<ul>
<li>Insmed expects topline data from the Phase 3 ASPEN study of brensocatib in adult patients with non-cystic fibrosis bronchiectasis in the latter part of the second quarter of 2024. If successful, the Company anticipates a launch in the U.S. in mid-2025, followed by launches in Europe and Japan in the first half of 2026.</li>
<li>The Data Safety Monitoring Committee for the ASPEN study held its fifth and final meeting in November 2023. No new safety signals were identified, and the Committee unanimously recommended that the trial continue as planned.</li>
<li>Insmed anticipates providing topline data from the Phase 2b BiRCh trial of brensocatib in patients with chronic rhinosinusitis without nasal polyps (CRSsNP) in 2025.</li>
<li>The Company expects to initiate a Phase 2 study of brensocatib in patients with hidradenitis suppurativa (HS)&nbsp;in the second half of 2024.</li>
</ul>
Pillar 3: TPIP
<ul>
<li>Insmed has completed enrollment in the Phase 2 study of treprostinil palmitil inhalation powder (TPIP) in pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company exceeded its enrollment target of 32 patients, with 39 patients enrolled. Topline data from the study are anticipated ahead of Phase 3 ASPEN data in the second quarter of 2024.</li>
<li>Enrollment in the Phase 2 study of TPIP in pulmonary arterial hypertension (PAH) remains ongoing. The Company anticipates enrolling 99 patients in the study, 45 of whom had been enrolled by year-end 2023, with topline results expected in 2025.</li>
</ul>
Pillar 4: Early-Stage Research
<ul>
<li>Insmed's early-stage research efforts include more than 30 identified pre-clinical programs in development, all of which have the potential to become first-in-class or best-in-class therapies.</li>
<li>The Company continues to anticipate that the totality of its early-stage research programs will comprise less than 20% of overall spend.</li>
</ul>
Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
Will Lewis, Chair and Chief Executive Officer of Insmed, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 3:00 p.m. PT (6:00 p.m. ET). A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4061184-1&amp;h=4280582607&amp;u=http%3A%2F%2Fwww.insmed.com%2F&amp;a=www.insmed.com">www.insmed.com</a>. A replay will also be archived for a period of 30 days following the conclusion of the live event.
About ARIKAYCE
ARIKAYCE is approved in the United States as ARIKAYCE&#xAE; (amikacin liposome inhalation suspension), in Europe as ARIKAYCE&#xAE; Liposomal 590 mg Nebuliser Dispersion, and in Japan as ARIKAYCE&#xAE; inhalation 590 mg (amikacin sulfate inhalation drug product). Current international treatment guidelines recommend the use of ARIKAYCE for appropriate patients. ARIKAYCE is a novel, inhaled, once-daily formulation of amikacin, an established antibiotic that was historically administered intravenously and associated with severe toxicity to hearing, balance, and kidney function. Insmed's proprietary PULMOVANCE&#xAE; liposomal technology enables the delivery of amikacin directly to the lungs, where liposomal amikacin is taken up by lung macrophages where the infection resides, while limiting systemic exposure. ARIKAYCE is administered once daily using the Lamira&#xAE; Nebulizer System manufactured by PARI Pharma GmbH (PARI).
About PARI Pharma and the Lamira&#xAE; Nebulizer System
ARIKAYCE is delivered by a novel inhalation device, the Lamira&#xAE; Nebulizer System, developed by PARI. Lamira&#xAE; is a quiet, portable nebulizer that enables efficient aerosolization of ARIKAYCE via a vibrating, perforated membrane. Based on PARI's 100-year history working with aerosols, PARI is dedicated to advancing inhalation therapies by developing innovative delivery platforms to improve patient care.
About Brensocatib
Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and result in excessive active NSPs that cause lung destruction and inflammation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs. Brensocatib is an investigational drug product that has not been approved for any indication in any jurisdiction.
About TPIP
Treprostinil palmitil inhalation powder (TPIP) is a dry powder formulation of treprostinil palmitil, a treprostinil prodrug consisting of treprostinil linked by an ester bond to a 16-carbon chain. Developed entirely in Insmed's laboratories, TPIP is a potentially highly differentiated prostanoid being evaluated for the treatment of patients with PAH, PH-ILD, and other rare and serious pulmonary disorders. TPIP is administered in a capsule-based inhalation device. TPIP is an investigational drug product that has not been approved for any indication in any jurisdiction.

Guidance

Events

Insmed Provides Business Update At 42nd Annual J.P. Morgan Healthcare Conference; Sees 2024 Global ARIKAYCE Revenues $340M-$360M; Delivers FY23 Revenues Exceeding The Upper End Of Guidance Range With Unaudited Global Net Product Sales Of ~$305.2M

Over the past 3 months, 7 analysts have published their opinion on Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
These 7 analysts have an average price target of $45.57 versus the current price of Insmed at $24.82, implying upside.
Below is a summary of how these 7 analysts rated Insmed over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock
<img src="https://www.benzinga.com/files/images/story/2023/1700499630_0.png" alt="price target chart" />
This current average has increased by 11.83% from the previous average price target of $40.75. 
<a href="https://www.benzinga.com/quote/INSM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Insmed analyst ratings.</a>
<h1>Analyst Ratings: What Are They?</h1>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Insmed Stands With Analysts

JP Morgan analyst Jessica Fye reinstates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Overweight and announces $36 price target.

JP Morgan Reinstates Overweight on Insmed, Announces $36 Price Target

WIIM

Insmed shares are trading lower after the company reported mixed Q3 financial results.

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) reported quarterly losses of $(1.11) per share which beat the analyst consensus estimate of $(1.12) by 0.89 percent. This is a 1.83 percent decrease over losses of $(1.09) per share from the same period last year. The company reported quarterly sales of $79.07 million which missed the analyst consensus estimate of $79.13 million by 0.07 percent. This is a 16.75 percent increase over sales of $67.73 million the same period last year.

Insmed Q3 GAAP EPS $(1.11) Beats $(1.12) Estimate, Sales $79.07M Miss $79.13M Estimate

Cantor Fitzgerald analyst Jennifer Kim maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Overweight and raises the price target from $46 to $54.

Cantor Fitzgerald Maintains Overweight on Insmed, Raises Price Target to $54

Cantor Fitzgerald analyst Jennifer Kim reiterates Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Overweight and maintains $46 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Insmed, Maintains $46 Price Target

Evercore ISI Group analyst Josh Schimmer maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Outperform and raises the price target from $32 to $42.

Evercore ISI Group Maintains Outperform on Insmed, Raises Price Target to $42

B of A Securities analyst Jason Zemansky maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $35 to $37.

B of A Securities Maintains Buy on Insmed, Raises Price Target to $37

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insmed (INSM – Research Report) and Zimmer Biomet Holdings (ZBH –...

Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and Zimmer Biomet Holdings (ZBH)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insmed (INSM – Research Report), Oric Pharmaceuticals (ORIC – Res...

Analysts Conflicted on These Healthcare Names: Insmed (INSM), Oric Pharmaceuticals (ORIC) and CytomX Therapeutics (CTMX)

Insmed (INSM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on March 15. Analyst Graig Suvannavejh from ...

Strong Endorsement and Market Expansion Potential Justify Buy Rating for Insmed's Brensocatib

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Annexon Biosciences (ANNX – Research Report) and Ins...

Analysts Are Bullish on Top Healthcare Stocks: Annexon Biosciences (ANNX), Insmed (INSM)

Wells Fargo's high-conviction tactical longs and shorts for Q2

ClearBridge Small Cap Growth Strategy Q2 2024 Portfolio Manager Commentary

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Insmed (INSM – Research Report) and UnitedHealth (UN...

Analysts Offer Insights on Healthcare Companies: Insmed (INSM) and UnitedHealth (UNH)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cartesian Therapeutics (RNAC – Research Report), I...

Analysts Conflicted on These Healthcare Names: Cartesian Therapeutics (RNAC), Insmed (INSM) and BioNTech SE (BNTX)

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

ALTM

AMZN

ANNX

ANTX

ARLTF

AVTE

BILL

BNTX

CASY

CNMD

CTMX

DUOL

FOXF

FWRD

GLAXF

GLBE

IART

INTA

IRDM

MEDP

MSTR

NVDA

OMCL

ORIC

RDNT

RNAC

SBUX

SHLS

SIRI

SITE

SMCI

SPRO

TREX

TSLA

VKTX

WING

XMTR

Press Releases

Insmed Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed to Host Fourth-Quarter and Full Year 2023 Financial Results Conference Call on Thursday, February 22, 2024

Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update

Actress Jane Seymour and Insmed Raise Awareness of "Unseenism" and Empower People to Speak Up When It Comes to Their Health

Insmed To Present at Three March Conferences

Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference